

Santen Announces Change of Representative Director of the Board

Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; President and CEO: Shigeo Taniuchi; hereinafter, the “Company”) today announced that its Board of Directors has approved the following management changes as described below.

1. Reason for changes

Santen previously announced its new Executive Management Team (herein after “EMT”) effective on April 1st, 2022. The newly formed EMT aims to enhance its competitiveness as a global company, increasing the capability of strategy implementation and realizing even greater growth over the medium to long-term. Appointment of the Representative Director of the Board, Executive Vice President will enable Santen to integrate expertise and insight of its core businesses including Japan into global strategic execution and further transform the Company into a truly global organization.

2. Details of the change effective April 1

Name	Newly Appointed	Current Position
Akira Kurokawa	Director of the Board, Chairman	Representative Director of the Board, Chairman
Takeshi Ito	Representative Director of the Board, Executive Vice President, Head of Japan Business, Head of Japan Sales and Marketing Division	Director of the Board, Executive Corporate Officer, Head of Japan Business, Head of Japan Sales and Marketing Division

3. Profile of the New Representative Director of the Board, Executive Vice President

Name Takeshi Ito
 Number of Shares held 23,554 (as of March, 2022)

Profile

Apr 1982 Joined the Company
 Dec 2002 Head of R&D Integration Department, R&D Division
 Apr 2007 Head of Surgical Division
 Apr 2012 Corporate Officer, Head of Prescription Pharmaceuticals Sales Department, Sales &Marketing Division, Prescription Pharmaceuticals
 Apr 2014 Senior Corporate Officer, Head of Japan Sales & Marketing Division, Prescription Pharmaceuticals
 Apr 2016 Executive Corporate Officer, Japan Business, Head of Japan Sales & Marketing Division, Prescription Pharmaceuticals
 Jun 2017 Director of the Board, Executive Corporate Officer, Japan Business, Head of Japan Sales & Marketing Division, Prescription Pharmaceuticals
 Apr 2019 Director of the Board, Executive Corporate Officer, Head of Japan Business, Head of Japan Sales & Marketing Division (incumbent)

(Reason for appointment)

Ito is a seasoned executive with a deep understanding of Santen CORE PRINCIPLE and its spirit behind. With a wealth of experience including Research and Development, surgical and pharmaceuticals business, he has led the Japanese business as part of core businesses at Santen, serving as Director of the Board, Executive Corporate Officer, Head of Japan Business, Head of Japan Sales & Marketing Division since 2019. In this position, Ito will lead the strategy and execution to roll-out global products through his expertise of customer-centric marketing and planning.

4. Timing of implementation

April 1, 2022

Contact:

Kaori Itagaki

General Manager, IR Group

E-mail: ir@santen.com Tel: +81-6-7664-8621

About Santen

As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in over 60 countries.

Toward realizing "WORLD VISION" (Happiness with Vision), the world Santen ultimately aspires to achieve, as a "Social Innovator", we aim to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around the world.

With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society.

For more information, please visit Santen's website (<https://www.santen.com/en/>).